Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for SOMATULINE DEPOT
- Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
- Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
- Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome
- A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula
- Lanreotide in the Treatment of Small Bowel Motility Disorders
- Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
- Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours
- Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues
- Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
- Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy
- Predictive Factors Study
- SOMATULINE Autogel 90 mg IN DUMPING SYNDROME
- A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
- Somatuline Predictive Factors in Acromegaly and NET
- Study of Lanreotide to Treat Polycystic Kidney Disease
- Acromegaly Combination Treatment Study
- Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma
- Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)
- Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
- An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
- Somatuline Autogel Preference and Health Economy Study
- Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
- Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
- Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
- Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
- Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
- Somatuline Autogel: Acromegaly Self/Partner Injection Study
Clinical trials list
click for details